The defense effect of domestic enhanced influenza vaccine has increased by four times.

A research team led by researcher Chi-Huey Wong Te and associate researcher Ma Che hired by the Genome Research Center of Academia Sinica has developed a monosaccharide influenza vaccine, which can resist the infection of cross-strain influenza virus, and its defense effect is 3-4 times higher than that of traditional influenza vaccine.

Traditional influenza vaccine is expected to overcome virus variation! Chi-Huey Wong, a special researcher of Genome Research Center of Chinese Academy of Sciences, and Ma Che, an associate researcher, led the research team to develop a monosaccharide influenza vaccine, which can resist the infection of cross-strain influenza virus, and the defense effect is 3-4 times higher than that of traditional influenza vaccine.

The ever-changing flu is not easy to eliminate monosaccharide.

Influenza virus will use the variation of its surface protein molecules to kill anti-host antibodies, so it is necessary to change the vaccine strain every year, otherwise it will not be able to resist the infectivity of influenza. Therefore, the production of influenza vaccine mainly solves the problem of vaccine failure due to the high variability of virus.

"It is a simple and practical method to make monosaccharide influenza vaccine with eggs, which can solve the problem of virus variation. Machel said that the team made a monosaccharide influenza vaccine against the hemagglutinin (HA) protein of influenza virus on the basis of the traditional method of culturing virus with eggs and the innovative single saccharification technology of influenza virus. Experiments show that, compared with the existing influenza virus vaccines, monosaccharide vaccines have more than 3-4 times the defense effect against different influenza viruses.

Preventive effect of broad-spectrum antivirus of sugar vaccine on virus subtypes

It is found that the HA antigen protein on influenza virus is responsible for helping the virus capture the host cell, which is covered with various polysaccharide molecules. Therefore, they first removed the string of sugar molecules on the surface protein of H 1N 1 influenza virus, leaving only one sugar molecule to keep its structure stable, and then made this monosaccharide virus into influenza vaccine.

The experimental results show that the vaccinated mice have a wide range of immune responses and can fight against the infection of different influenza viruses. Because removing the sugar molecules of the virus surface protein is like removing the disguise of the virus, so that it can hide from the immune system. In order to achieve the latest solution, the research team set up a vaccine manufacturing and production platform, and used the embryo eggs fertilized for about 10 days to produce monosaccharide influenza vaccine without cross-subtype restrictions within 1 week.

The achievement of helping immune cells fight infection has won many patents.

Mache said that HA protein is like a mushroom, and its head is prone to mutation to escape the host's immune response. The stem is protected by sugar molecules to prevent it from being recognized by host immune cells. Therefore, monosaccharide influenza vaccine can effectively attack the virus stem when it produces antibodies in vivo. The researchers also found that antibody-dependent cell-mediated cytotoxicity (ADCC) will occur in cells infected by virus, and immune cells in patients will clean up cells invaded by influenza virus.

Academia Sinica pointed out that this research result was published in PNAS in February this year (108), which obtained multinational patents, and relevant units signed technology transfer contracts with multinational pharmaceutical companies.

Join us and pay attention to your health every day! Line @ ID: @ Subscribe to health ALOHO audio-visual channel to read health knowledge more easily:/beauty/article/41361Keywords: influenza, vaccine, influenza virus, Academia Sinica, sugar vaccine, fever.